JP2015520161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520161A5 JP2015520161A5 JP2015512644A JP2015512644A JP2015520161A5 JP 2015520161 A5 JP2015520161 A5 JP 2015520161A5 JP 2015512644 A JP2015512644 A JP 2015512644A JP 2015512644 A JP2015512644 A JP 2015512644A JP 2015520161 A5 JP2015520161 A5 JP 2015520161A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mammal
- nucleic acid
- aav
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648801P | 2012-05-18 | 2012-05-18 | |
| US61/648,801 | 2012-05-18 | ||
| PCT/US2013/031725 WO2013172964A1 (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207331A Division JP2019031564A (ja) | 2012-05-18 | 2018-11-02 | アミロイドの沈着を処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520161A JP2015520161A (ja) | 2015-07-16 |
| JP2015520161A5 true JP2015520161A5 (enExample) | 2016-05-12 |
| JP6469000B2 JP6469000B2 (ja) | 2019-02-13 |
Family
ID=49584137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512644A Active JP6469000B2 (ja) | 2012-05-18 | 2013-03-14 | アミロイドの沈着を処置するための方法および組成物 |
| JP2018207331A Pending JP2019031564A (ja) | 2012-05-18 | 2018-11-02 | アミロイドの沈着を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207331A Pending JP2019031564A (ja) | 2012-05-18 | 2018-11-02 | アミロイドの沈着を処置するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150183850A1 (enExample) |
| EP (1) | EP2850195B1 (enExample) |
| JP (2) | JP6469000B2 (enExample) |
| CN (2) | CN104540952A (enExample) |
| AU (1) | AU2013263346B2 (enExample) |
| BR (1) | BR112014028666B1 (enExample) |
| CA (1) | CA2873890C (enExample) |
| ES (1) | ES2786078T3 (enExample) |
| HK (1) | HK1207109A1 (enExample) |
| IN (1) | IN2014KN02672A (enExample) |
| RU (1) | RU2673484C2 (enExample) |
| WO (1) | WO2013172964A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112375760A (zh) | 2014-11-14 | 2021-02-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| US11027024B2 (en) | 2015-05-29 | 2021-06-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| EP3307391A1 (en) * | 2015-06-12 | 2018-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| EP3444344A4 (en) * | 2016-04-14 | 2020-02-19 | TAO Health Life Pharma Co., Ltd. | AMYLOSPHEROID TYPE STRUCTURE (ASPD) AND PHARMACEUTICAL COMPOSITION |
| CN117904112A (zh) | 2016-05-18 | 2024-04-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| CA3032697A1 (en) * | 2016-08-03 | 2018-02-08 | University Of South Florida | Reelin compositions for treatment of neurological disorders |
| WO2018045347A1 (en) * | 2016-09-02 | 2018-03-08 | Spark Therapeutics, Inc. | Methods and vectors for treating cns disorders |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| MX2020003965A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| KR20220082050A (ko) * | 2019-10-16 | 2022-06-16 | 코넬 유니버시티 | 알츠하이머병에 대한 유전자 요법 |
| IL296494A (en) * | 2020-03-31 | 2022-11-01 | Nuo Beta Pharmarceutical Tech Shanghai Co Ltd | Deuterated oxophenylarsine compound and use thereof |
| CN116670291A (zh) * | 2020-11-25 | 2023-08-29 | 普利维尔治疗公司 | 用于神经退行性疾病的基因疗法 |
| WO2023108507A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Recombinant aav vectors and use thereof |
| CN116063405B (zh) * | 2022-09-27 | 2025-08-29 | 广州译码基因科技有限公司 | 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US6436996B1 (en) * | 1997-09-30 | 2002-08-20 | Duke University | Modulation of nitric oxide production |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| EP1828390B1 (en) * | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| DK1879623T3 (da) * | 2005-05-02 | 2012-12-17 | Genzyme Corp | Genterapi til rygmarvssygdomme |
| CN102886052B (zh) * | 2006-09-14 | 2014-07-30 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| CA2684946C (en) * | 2007-05-16 | 2015-03-31 | The Brigham And Women's Hospital, Inc. | Treatment of synucleinopathies |
| EP2561075B1 (en) * | 2010-04-23 | 2018-06-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
-
2013
- 2013-03-14 BR BR112014028666-3A patent/BR112014028666B1/pt active IP Right Grant
- 2013-03-14 US US14/402,064 patent/US20150183850A1/en not_active Abandoned
- 2013-03-14 ES ES13790429T patent/ES2786078T3/es active Active
- 2013-03-14 RU RU2014151218A patent/RU2673484C2/ru active
- 2013-03-14 IN IN2672KON2014 patent/IN2014KN02672A/en unknown
- 2013-03-14 JP JP2015512644A patent/JP6469000B2/ja active Active
- 2013-03-14 EP EP13790429.8A patent/EP2850195B1/en active Active
- 2013-03-14 HK HK15107526.1A patent/HK1207109A1/xx unknown
- 2013-03-14 AU AU2013263346A patent/AU2013263346B2/en active Active
- 2013-03-14 CN CN201380038140.1A patent/CN104540952A/zh active Pending
- 2013-03-14 CA CA2873890A patent/CA2873890C/en active Active
- 2013-03-14 CN CN202011133829.0A patent/CN112574964A/zh active Pending
- 2013-03-14 WO PCT/US2013/031725 patent/WO2013172964A1/en not_active Ceased
-
2018
- 2018-11-02 JP JP2018207331A patent/JP2019031564A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520161A5 (enExample) | ||
| Kim et al. | GDF-15 secreted from human umbilical cord blood mesenchymal stem cells delivered through the cerebrospinal fluid promotes hippocampal neurogenesis and synaptic activity in an Alzheimer's disease model | |
| RU2014151218A (ru) | Способы и композиции для лечения амилоидных отложений | |
| Clausen et al. | Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia | |
| JP2018520646A5 (enExample) | ||
| JP2016500648A5 (enExample) | ||
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| JP2015518818A5 (enExample) | ||
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| EA201590353A1 (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| WO2015158749A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| JP2015530404A5 (enExample) | ||
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| JP2014513952A5 (enExample) | ||
| JP2018509388A5 (enExample) | ||
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| BR112019009074A2 (pt) | composições, métodos e uso de transferência genética para o tratamento de doenças neurodegenerativas | |
| JP2015514115A5 (enExample) | ||
| McCall et al. | Pathogen-inspired drug delivery to the central nervous system | |
| RU2017128296A (ru) | Композиция для лечения бесплодия | |
| EA201991015A1 (ru) | Модифицированные пептиды |